Open Access
Prospects for introducing deferiprone as potent pharmaceutical antioxidant
George J Kontoghiorghes1
Postgraduate Research Institute of Science, Technology, Environment and Medicine, Limassol, Cyprus.
DOI: 10.2741/E16 Volume 1 Issue 1, pp.161-178
Published: 01 June 2009

Free radical formation is primarily initiated from metal catalytic centers involving iron and copper. Under certain conditions, free radical reactions can lead to free radical cascades and oxidative stress, which can cause biomolecular, cellular and tissue damage (FRD). The use of natural antioxidants to prevent FRD is in most cases not effective. Many chelators have been shown to inhibit free radical reactions and toxicity in experimental models of both in vitro and in vivo. Deferiprone (L1) has been shown to be effective and safe in the reversal of accelerating oxidative stress related tissue damage in iron loading and non iron loading conditions such as cardiomyopathy in thalassaemia, acute kidney disease and Friedreich ataxia. The selection of chelating drugs and their combinations could be used as new strategies for antioxidant therapies. In vitro, in vivo and clinical data suggest that L1 is the most potent drug antioxidant because of its high therapeutic index, ability to reach extracellular and intracellular compartments of many tissues and ability to inhibit both iron and copper catalysed free radical reactions.

Share and Cite
George J Kontoghiorghes. Prospects for introducing deferiprone as potent pharmaceutical antioxidant. Frontiers in Bioscience-Elite. 2009. 1(1); 161-178.